1
|
Powers TW, Mullins EK, Zhang K, Binder JJ, Friese O, Runnels HA, Thompson LC. Identification of Recombinant Chimpanzee Adenovirus C68 Degradation Products Detected by AEX-HPLC. Front Bioeng Biotechnol 2022; 10:753481. [PMID: 35449595 PMCID: PMC9017566 DOI: 10.3389/fbioe.2022.753481] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2021] [Accepted: 03/09/2022] [Indexed: 12/01/2022] Open
Abstract
Physicochemical tests represent important tools for the analytical control strategy of biotherapeutics. For adenoviral modalities, anion-exchange high performance liquid chromatography (AEX-HPLC) represents an important methodology, as it is able to simultaneously provide information on viral particle concentration, product purity and surface charge in a high-throughput manner. During product development of an adenoviral-based therapeutic, an accelerated stability study was performed and showed changes in each of the AEX-HPLC reportable attributes. These changes also correlated with a decrease in product infectivity prompting a detailed characterization of the impurity and mechanism of the surface charge change. Characterization experiments identified the impurity to be free hexon trimer, suggesting that capsid degradation could be contributing to both the impurity and reduced particle concentration. Additional mass spectrometry characterization identified deamidation of specific hexon residues to be associated with the external surface charge modification observed upon thermal stress conditions. To demonstrate a causal relationship between deamidation and surface charge changes observed by AEX-HPLC, site-directed mutagenesis experiments were performed. Through this effort, it was concluded that deamidation of asparagine 414 was responsible for the surface charge alteration observed in the AEX-HPLC profile but was not associated with the reduction in infectivity. Overall, this manuscript details critical characterization efforts conducted to enable understanding of a pivotal physicochemical test for adenoviral based therapeutics.
Collapse
Affiliation(s)
- Thomas W. Powers
- Analytical Research and Development, Biotherapeutic Pharmaceutical Sciences, Pfizer Inc., Chesterfield, MO, United States
| | - Elise K. Mullins
- Analytical Research and Development, Biotherapeutic Pharmaceutical Sciences, Pfizer Inc., Chesterfield, MO, United States
| | - Kun Zhang
- Analytical Research and Development, Biotherapeutic Pharmaceutical Sciences, Pfizer Inc., Chesterfield, MO, United States
| | - Joseph J. Binder
- Cancer Vaccines and Immunotherapeutics, Pfizer Inc., San Diego, CA, United States
| | - Olga Friese
- Analytical Research and Development, Biotherapeutic Pharmaceutical Sciences, Pfizer Inc., Chesterfield, MO, United States
| | - Herbert A. Runnels
- Analytical Research and Development, Biotherapeutic Pharmaceutical Sciences, Pfizer Inc., Chesterfield, MO, United States
| | - Lawrence C. Thompson
- Analytical Research and Development, Biotherapeutic Pharmaceutical Sciences, Pfizer Inc., Chesterfield, MO, United States
- *Correspondence: Lawrence C. Thompson,
| |
Collapse
|
2
|
Mullins EK, Powers TW, Zobel J, Clawson KM, Barnes LF, Draper BE, Zou Q, Binder JJ, Dai S, Zhang K, Friese O, Runnels HA, Jarrold MF, Thompson LC. Characterization of Recombinant Chimpanzee Adenovirus C68 Low and High-Density Particles: Impact on Determination of Viral Particle Titer. Front Bioeng Biotechnol 2021; 9:753480. [PMID: 34805110 PMCID: PMC8599148 DOI: 10.3389/fbioe.2021.753480] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2021] [Accepted: 10/20/2021] [Indexed: 12/03/2022] Open
Abstract
We observed differential infectivity and product yield between two recombinant chimpanzee adenovirus C68 constructs whose primary difference was genome length. To determine a possible reason for this outcome, we characterized the proportion and composition of the empty and packaged capsids. Both analytical ultracentrifugation (AUC) and differential centrifugation sedimentation (DCS, a rapid and quantitative method for measuring adenoviral packaging variants) were employed for an initial assessment of genome packaging and showed multiple species whose abundance deviated between the virus builds but not manufacturing campaigns. Identity of the packaging variants was confirmed by charge detection mass spectrometry (CDMS), the first known application of this technique to analyze adenovirus. The empty and packaged capsid populations were separated via preparative ultracentrifugation and then combined into a series of mixtures. These mixtures showed the oft-utilized denaturing A260 adenoviral particle titer method will underestimate the actual particle titer by as much as three-fold depending on the empty/full ratio. In contrast, liquid chromatography with fluorescence detection proves to be a superior viral particle titer methodology.
Collapse
Affiliation(s)
- Elise K Mullins
- Analytical Research and Development, Biotherapeutic Pharmaceutical Sciences, Pfizer Inc., Chesterfield, MO, United States
| | - Thomas W Powers
- Analytical Research and Development, Biotherapeutic Pharmaceutical Sciences, Pfizer Inc., Chesterfield, MO, United States
| | - Jim Zobel
- Analytical Research and Development, Biotherapeutic Pharmaceutical Sciences, Pfizer Inc., Chesterfield, MO, United States
| | - Kory M Clawson
- Analytical Research and Development, Biotherapeutic Pharmaceutical Sciences, Pfizer Inc., Chesterfield, MO, United States
| | - Lauren F Barnes
- Chemistry Department, Indiana University, Bloomington, IN, United States
| | | | - Qin Zou
- Analytical Research and Development, Biotherapeutic Pharmaceutical Sciences, Pfizer Inc., Chesterfield, MO, United States
| | - Joseph J Binder
- Cancer Vaccines and Immunotherapies, Pfizer Inc., San Diego, CA, United States
| | - Stanley Dai
- Nektar Therapeutics, San Francisco, CA, United States
| | - Kun Zhang
- Analytical Research and Development, Biotherapeutic Pharmaceutical Sciences, Pfizer Inc., Chesterfield, MO, United States
| | - Olga Friese
- Analytical Research and Development, Biotherapeutic Pharmaceutical Sciences, Pfizer Inc., Chesterfield, MO, United States
| | - Herbert A Runnels
- Analytical Research and Development, Biotherapeutic Pharmaceutical Sciences, Pfizer Inc., Chesterfield, MO, United States
| | - Martin F Jarrold
- Chemistry Department, Indiana University, Bloomington, IN, United States
| | - Lawrence C Thompson
- Analytical Research and Development, Biotherapeutic Pharmaceutical Sciences, Pfizer Inc., Chesterfield, MO, United States
| |
Collapse
|
3
|
Luo Y, Friese OV, Runnels HA, Khandke L, Zlotnick G, Aulabaugh A, Gore T, Vidunas E, Raso SW, Novikova E, Byrne E, Schlittler M, Stano D, Dufield RL, Kumar S, Anderson AS, Jansen KU, Rouse JC. The Dual Role of Lipids of the Lipoproteins in Trumenba, a Self-Adjuvanting Vaccine Against Meningococcal Meningitis B Disease. AAPS J 2016; 18:1562-1575. [PMID: 27604766 DOI: 10.1208/s12248-016-9979-x] [Citation(s) in RCA: 47] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/30/2016] [Accepted: 08/17/2016] [Indexed: 01/02/2023]
Abstract
Trumenba (bivalent rLP2086) is a vaccine licensed for the prevention of meningococcal meningitis disease caused by Neisseria meningitidis serogroup B (NmB) in individuals 10-25 years of age in the USA. The vaccine is composed of two factor H binding protein (fHbp) variants that were recombinantly expressed in Escherichia coli as native lipoproteins: rLP2086-A05 and rLP2086-B01. The vaccine was shown to induce potent bactericidal antibodies against a broad range of NmB isolates expressing fHbp that were different in sequence from the fHbp vaccine antigens. Here, we describe the characterization of the vaccine antigens including the elucidation of their structure which is characterized by two distinct motifs, the polypeptide domain and the N-terminal lipid moiety. In the vaccine formulation, the lipoproteins self-associate to form micelles driven by the hydrophobicity of the lipids and limited by the size of the folded polypeptides. The micelles help to increase the structural stability of the lipoproteins in the absence of bacterial cell walls. Analysis of the lipoproteins in Toll-like receptor (TLR) activation assays revealed their TLR2 agonist activity. This activity was lost with removal of the O-linked fatty acids, similar to removal of all lipids, demonstrating that this moiety plays an adjuvant role in immune activation. The thorough understanding of the structure and function of each moiety of the lipoproteins, as well as their relationship, lays the foundation for identifying critical parameters to guide vaccine development and manufacture.
Collapse
Affiliation(s)
- Yin Luo
- Pfizer Biotherapeutics Pharmaceutical Sciences, 1 Burtt Rd., Andover, Massachusetts, USA.
| | - Olga V Friese
- Pfizer Biotherapeutics Pharmaceutical Sciences, 700 Chesterfield Pkwy W, St. Louis, Missouri, USA
| | - Herbert A Runnels
- Pfizer Biotherapeutics Pharmaceutical Sciences, 700 Chesterfield Pkwy W, St. Louis, Missouri, USA
| | - Lakshmi Khandke
- Pfizer Vaccine Research and Development, 401 N. Middletown Rd., Pearl River, New York, USA
| | - Gary Zlotnick
- Pfizer Vaccine Research and Development, 401 N. Middletown Rd., Pearl River, New York, USA
| | - Ann Aulabaugh
- Pfizer Worldwide Research, 558 Eastern Point Rd., Groton, Connecticut, USA
| | - Thomas Gore
- Pfizer Biotherapeutics Pharmaceutical Sciences, 401 N. Middletown Rd., Pearl River, New York, USA
| | - Eugene Vidunas
- Pfizer Vaccine Research and Development, 401 N. Middletown Rd., Pearl River, New York, USA
| | - Stephen W Raso
- Pfizer Biotherapeutics Pharmaceutical Sciences, 1 Burtt Rd., Andover, Massachusetts, USA
| | - Elena Novikova
- Pfizer Vaccine Research and Development, 401 N. Middletown Rd., Pearl River, New York, USA
| | - Emilia Byrne
- Pfizer Biotherapeutics Pharmaceutical Sciences, 700 Chesterfield Pkwy W, St. Louis, Missouri, USA
| | - Michael Schlittler
- Pfizer Biotherapeutics Pharmaceutical Sciences, 700 Chesterfield Pkwy W, St. Louis, Missouri, USA
| | - Donald Stano
- Pfizer Biotherapeutics Pharmaceutical Sciences, 700 Chesterfield Pkwy W, St. Louis, Missouri, USA
| | - Robert L Dufield
- Pfizer Biotherapeutics Pharmaceutical Sciences, 1 Burtt Rd., Andover, Massachusetts, USA
| | - Sandeep Kumar
- Pfizer Biotherapeutics Pharmaceutical Sciences, 700 Chesterfield Pkwy W, St. Louis, Missouri, USA
| | - Annaliesa S Anderson
- Pfizer Vaccine Research and Development, 401 N. Middletown Rd., Pearl River, New York, USA
| | - Kathrin U Jansen
- Pfizer Vaccine Research and Development, 401 N. Middletown Rd., Pearl River, New York, USA
| | - Jason C Rouse
- Pfizer Biotherapeutics Pharmaceutical Sciences, 1 Burtt Rd., Andover, Massachusetts, USA.
| |
Collapse
|
4
|
Wang B, Zinselmeyer BH, Runnels HA, LaBranche TP, Morton PA, Kreisel D, Mack M, Nickerson-Nutter C, Allen PM, Miller MJ. In vivo imaging implicates CCR2(+) monocytes as regulators of neutrophil recruitment during arthritis. Cell Immunol 2012; 278:103-12. [PMID: 23121982 DOI: 10.1016/j.cellimm.2012.07.005] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2011] [Revised: 05/31/2012] [Accepted: 07/16/2012] [Indexed: 01/06/2023]
Abstract
The infiltration of neutrophils and monocytes is a prominent feature of inflammatory diseases including human rheumatoid arthritis. Understanding how neutrophil recruitment is regulated during pathogenesis is crucial for developing anti-inflammatory therapies. We optimized the K/B×N serum-induced mouse arthritis model to study neutrophil trafficking dynamics in vivo using two-photon microscopy. Arthritogenic serum was injected subcutaneously into one hind footpad to induce a local arthritis with robust neutrophil recruitment. Using this approach, we showed that the depletion of monocytes with clodronate liposomes impaired neutrophil recruitment specifically at the transendothelial migration step. The depletion of CCR2(+) monocytes with the monoclonal antibody MC-21 reproduced these effects, implicating CCR2(+) monocytes as key regulators of neutrophil extravasation during arthritis initiation. However, monocyte depletion did not prevent neutrophil extravasation in response to bacterial challenge. These findings suggest that anti-inflammatory therapies targeting monocytes may act in part through antagonizing neutrophil extravasation at sites of aseptic inflammation.
Collapse
Affiliation(s)
- Baomei Wang
- Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Runnels HA, Arbuckle JA, Bailey KS, Nicastro PJ, Sun D, Pegg JA, Meyer DM, Evans M, Bono CP, Lie WR, Moffat MA, Casperson GF, Lennard S, Elvin J, Vaughan T, Smith CE, Morton PA. Human monoclonal antibodies to the insulin-like growth factor 1 receptor inhibit receptor activation and tumor growth in preclinical studies. Adv Ther 2010; 27:458-75. [PMID: 20574692 DOI: 10.1007/s12325-010-0026-5] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2010] [Indexed: 11/28/2022]
Abstract
INTRODUCTION The insulin-like growth factor type 1 (IGF-1) receptor contributes importantly to transformation and survival of tumor cells both in vitro and in vivo, and selective antagonists of the IGF-1 receptor (IGF-1R) activity represent an attractive experimental approach for human cancer therapy. METHODS Using a phage display library, we identified several high-affinity fully human monoclonal antibodies with inhibitory activity against both human and rodent IGF.1Rs. RESULTS These candidate therapeutic antibodies recognized several distinct epitopes and effectively blocked ligand-mediated receptor signal transduction and cellular proliferation in vitro. They also induced IGF-1R downregulation and catabolism following antibody-mediated endocytosis. These antibodies exhibited activity against human, primate, and rodent IGF-1Rs, and dose-dependently inhibited the growth of established human tumors in nude mice. CONCLUSION These fully human antibodies therefore have the potential to provide an effective anti-tumor biological therapy in the human clinical setting.
Collapse
|
6
|
Runnels HA, Weber GL, Min J, Kudlacz EM, Zobel JF, Donovan CB, Thiede MA, Zhang J, Alpert RB, Salafia MA, Milici AJ, Burdette D, Bell RR, Beebe JS, Xu X. PF-03475952: a potent and neutralizing fully human anti-CD44 antibody for therapeutic applications in inflammatory diseases. Adv Ther 2010; 27:168-80. [PMID: 20429046 DOI: 10.1007/s12325-010-0010-0] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2010] [Indexed: 12/11/2022]
Abstract
INTRODUCTION CD44 is a cell adhesion molecule believed to play a critical role in T cell and monocyte infiltration in the inflammatory process. The reduction of CD44 expression or its ability to properly interact with its key ligand, hyaluronic acid (HA), inhibits migration and subsequent activation of cells within sites of inflammation. CD44-deficient mice exhibit decreased disease in a mouse arthritis model. METHODS Accordingly, we developed PF-03475952, a fully human IgG2 anti-CD44 monoclonal antibody (mAb). RESULTS Binding of PF-03475952 to CD44 inhibits binding of HA and induces loss of CD44 from the cell surface. PF-03475952 also passed a series of safety pharmacology assays designed to assess the risk of the mAb to bind Fc gamma receptors, stimulate cytokine release from human whole blood, and stimulate cytokine release from peripheral blood mononuclear cells (PBMC) using plate-bound antibodies. The latter assay was designed specifically to evaluate the risk of cytokine storm that had been observed with TGN1412 (immunostimulatory CD28 superagonist mAb). PF-003475952 exhibits high-affinity binding to both human and cynomolgus monkey CD44, but does not cross-react with rodent CD44. Thus, a rat anti-mouse CD44 mAb was used to demonstrate a dose-dependent decrease of disease in mouse collagen-induced arthritis. Importantly, efficacy was correlated with >50% loss of cell surface CD44 on circulating cells. Loss of CD44 expression on CD3+ lymphocytes was monitored following a single dose of PF-03475952 in cynomolgus monkeys as a pharmacodynamic marker. The recovery of CD44 expression was found to be dose-dependent. PF-03475952 doses of 1, 10, and 100 mg/kg reduced CD44 expression below 50% for 218, 373, and >504 hours, respectively. CONCLUSION Targeting of CD44 is a unique mechanism of action in the treatment of inflammatory diseases and is expected to reduce joint damage induced by inflammatory mediators, resulting in disease modification in inflammatory diseases such as rheumatoid arthritis.
Collapse
MESH Headings
- Animals
- Anti-Inflammatory Agents/pharmacology
- Anti-Inflammatory Agents/therapeutic use
- Antibodies, Monoclonal/pharmacology
- Antibodies, Monoclonal/therapeutic use
- Antibodies, Monoclonal, Humanized
- Antibodies, Neutralizing/pharmacology
- Antibodies, Neutralizing/therapeutic use
- Arthritis, Experimental/drug therapy
- Arthritis, Experimental/immunology
- Arthritis, Experimental/metabolism
- Cytokines/blood
- Enzyme-Linked Immunosorbent Assay
- Humans
- Hyaluronan Receptors/immunology
- Hyaluronan Receptors/metabolism
- Hyaluronic Acid/metabolism
- Immunoglobulin G/pharmacology
- Immunoglobulin G/therapeutic use
- Macaca fascicularis
- Male
- Mice
- Mice, Inbred DBA
- Platelet Activation/drug effects
- Protein Binding
Collapse
Affiliation(s)
- Herbert A Runnels
- Pfizer Global Research and Development, St. Louis Laboratories, Chesterfield, MO 63017, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Barton LF, Runnels HA, Schell TD, Cho Y, Gibbons R, Tevethia SS, Deepe GS, Monaco JJ. Immune Defects in 28-kDa Proteasome Activator γ-Deficient Mice. J Immunol 2004; 172:3948-54. [PMID: 15004203 DOI: 10.4049/jimmunol.172.6.3948] [Citation(s) in RCA: 94] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Protein complexes of the 28-kDa proteasome activator (PA28) family activate the proteasome and may alter proteasome cleavage specificity. Initial investigations have demonstrated a role for the IFN-gamma-inducible PA28alpha/beta complex in Ag processing. Although the noninducible and predominantly nuclear PA28gamma complex has been implicated in affecting proteasome-dependent signaling pathways, such as control of the mitotic cell cycle, there is no previous evidence demonstrating a role for this structure in Ag processing. We therefore generated PA28gamma-deficient mice and investigated their immune function. PA28gamma(-/-) mice display a slight reduction in CD8+ T cell numbers and do not effectively clear a pulmonary fungal infection. However, T cell responses in two viral infection models appear normal in both magnitude and the hierarchy of antigenic epitopes recognized. We conclude that PA28gamma(-/-) mice, like PA28alpha(-/-)/beta(-/-) mice, are deficient in the processing of only specific Ags.
Collapse
Affiliation(s)
- Lance F Barton
- Department of Molecular Genetics, Biochemistry, and Microbiology, University of Cincinnati, Cincinnati, OH 45267, USA
| | | | | | | | | | | | | | | |
Collapse
|
8
|
|
9
|
Fang CH, Li BG, Fischer DR, Wang JJ, Runnels HA, Monaco JJ, Hasselgren PO. Burn injury upregulates the activity and gene expression of the 20 S proteasome in rat skeletal muscle. Clin Sci (Lond) 2000; 99:181-7. [PMID: 11787469] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]
Abstract
There is evidence that burn injury stimulates ubiquitin-proteasome-dependent protein breakdown in skeletal muscle. In this proteolytic pathway, protein substrates are conjugated to multiple molecules of ubiquitin, whereafter they are recognized, unfolded and degraded by the multicatalytic 26 S protease complex. The 20 S proteasome is the catalytic core of the 26 S protease complex. The influence of burn injury on the expression and activity of the 20 S proteasome has not been reported. We tested the hypothesis that burn injury increases 20 S proteasome activity and the expression of mRNA for the 20 S proteasome subunits RC3 and RC7. Proteolytic activity of isolated 20 S proteasomes, assessed as activity against fluorogenic peptide substrates, was increased in extensor digitorum longus muscles from burned rats. Northern-blot analysis revealed that the expression of mRNA for RC3 and RC7 was increased by 100% and 80% respectively following burn injury. Increased activity and expression of the 20 S proteasome in muscles from burned rats support the concept that burn-induced muscle cachexia is at least, in part, regulated by the ubiquitin-proteasome proteolytic pathway.
Collapse
Affiliation(s)
- C H Fang
- The Shriners Hospital for Children, Cincinnati, OH 45229, USA
| | | | | | | | | | | | | |
Collapse
|
10
|
Abstract
The ability of intact protein antigens to bind to purified class II histocompatibility molecules was investigated. Intact bovine ribonuclease (RNase) inhibited peptide binding to DR1 with a potency similar to that of a high affinity peptide or irreversibly denatured RNase. Similarly, horse myoglobin (Mb) was a potent inhibitor of peptide binding to I-E(k). I-E(k)-Mb complexes were directly visualized as a distinct band with reduced mobility on SDS PAGE. Direct binding experiments with biotin-labeled proteins demonstrated that Mb and RNase bind to class II molecules through the peptide-binding groove with high affinity, and that binding occurs in the absence of detergent. The possibility that HLA-DM can catalyse the binding of intact protein antigens was supported by the observation that DM enhances the binding of biotin-RNase to DR1. Our results provide further support for the hypothesis that intact, partially unfolded protein antigens can act as ligands for initial interaction with class II molecules.
Collapse
Affiliation(s)
- H A Runnels
- Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia 30322, U.S.A
| | | | | | | | | |
Collapse
|
11
|
Abstract
Peptide binding by class II major histocompatibility complex proteins is generally enhanced at low pH in the range of hydrogen ion concentrations found in the endosomal compartments of antigen-presenting cells. We and others have proposed that class II molecules undergo a reversible conformational change at low pH that is associated with enhanced peptide loading. However, no one has previously provided direct evidence for a structural change in class II proteins in the mildly acidic pH conditions in which enhanced peptide binding is observed. In this study, susceptibility to denaturation induced by sodium dodecyl sulfate (SDS) detergent or heat was used to probe the conformation of class II at different hydrogen ion concentrations. Class II molecules became sensitive to denaturation at pH 5.5-6.5 depending on the allele and experimental conditions. The observed structural transition was fully reversible if acidic pH was neutralized before exposure to SDS or heat. Experiments with the environment-sensitive fluorescent probe ANS (8-anilino-1-naphthalene-sulfonic acid) provided further evidence for a reversible structural transition at mildly acidic pH associated with an increase in exposed hydrophobicity in class II molecules. IAd conformation was found to change at a higher pH than IEd, IEk, or IAk, which correlates with the different pH optimal for peptide binding by these molecules. We conclude that pH regulates peptide binding by influencing the structure of class II molecules.
Collapse
Affiliation(s)
- H A Runnels
- Department of Pathology, Emory University School of Medicine, Atlanta, Georgia 30322, USA
| | | | | |
Collapse
|
12
|
Abstract
We analyzed the binding of an influenza matrix protein-derived peptide, MAT(17-31), to cell surface and purified DR1. The pH dependence of peptide binding was dramatically influenced by the membrane environment. Cell surface binding was enhanced at low pH, with little or no binding detected at neutral pH and optimal binding at pH 4. By contrast, hydrogen ion concentration had minimal effect on peptide binding to purified DR1. Exposure to low pH in the absence of peptide did not affect the peptide binding capacity of cell-associated DR1. Purified DR1 was stable at low pH, excluding the possibility that enhanced binding was offset by a competing denaturation event at low pH. The striking effect of pH on peptide binding characteristic of cell surface DR1 was recovered after reconstitution of purified DR1 in B cell membranes by detergent dialysis. This behavior was partially recovered by reconstitution of full-length, but not truncated DR1 in vesicles containing purified lipid. Our results demonstrate that interactions involving membrane components influence the peptide-binding behavior of DR1.
Collapse
Affiliation(s)
- M A Sherman
- Department of Pathology, Emory University School of Medicine, Atlanta, Georgia 30322
| | | | | | | | | |
Collapse
|
13
|
Newton DW, Runnels HA, Kearns RJ. Enhanced splenic bacterial clearance and neutrophilia in anti-NK1.1-treated mice infected with Pseudomonas aeruginosa. Nat Immun 1992; 11:335-44. [PMID: 1477496] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
The purpose of the present study was to further delineate the role of natural killer (NK) cells in the early stages of resistance to infection by Pseudomonas aeruginosa, strain PAO1. Intravenous injection of the monoclonal antibody alpha-NK1.1 resulted in an 82% reduction in NK cell activity of normal mice, as measured by a standard 4-hour 51Cr release assay. Splenic bacterial clearance was examined in mice treated with this antibody 12 h prior to infection with a sublethal dose (10(6)) of PAO1. At 2, 4, and 6 h postinfection there was significant enhancement (up to 10-fold) of clearance in mice treated with alpha-NK1.1 when compared to untreated infected control animals. Interestingly, the enhanced clearance of PAO1 in the spleens of NK-depleted mice was found to be coupled to a significant increase in neutrophils. Normal murine spleens were found to contain 1-2% neutrophils, which increased to 6-7% following sublethal infection. However, in mice treated with alpha-NK1.1 and infected, splenic neutrophils increased up to 15% during the early stages of infection. The data presented here suggests that NK cells do not have direct bactericidal activity against Pseudomonas, but may regulate other effector cells, such as neutrophils-an indirect role for natural killer cells, probably mediated in vivo by their production and secretion of cytokines.
Collapse
Affiliation(s)
- D W Newton
- Department of Biology, University of Dayton, OH 45469-2320
| | | | | |
Collapse
|